Related Experiment Video
Updated: Jun 27, 2025
03:42
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
1.5K
Obesity and heart failure with preserved ejection fraction
Tetyana M Ternushchak1, Marianna I Tovt-Korshynska1, Oksana M Moskal1
1UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|May 1, 2024
Summary
Central obesity in heart failure with preserved ejection fraction (HFpEF) patients is linked to worse diastolic dysfunction and increased cardiovascular risk factors. These patients exhibit higher inflammatory markers and lipid profiles despite lower NT-proBNP levels.
Area of Science:
- Cardiology
- Obesity Medicine
- Cardiovascular Research
Background:
- Heart failure with preserved ejection fraction (HFpEF) is a growing clinical challenge.
- Central obesity is increasingly recognized as a significant comorbidity impacting cardiovascular health.
- Understanding the specific effects of central obesity on HFpEF is crucial for risk stratification and management.
Purpose of the Study:
- To comprehensively assess the clinical and echocardiographic characteristics of HFpEF patients with central obesity.
- To compare these characteristics against HFpEF patients without obesity and healthy controls.
- To identify specific cardiovascular risks associated with central obesity in the HFpEF population.
Main Methods:
- Enrolled 73 HFpEF patients with central obesity and 70 HFpEF patients without obesity, alongside 69 age-matched healthy controls.
- Conducted physical examinations and collected data on fasting glucose, insulin, lipid profiles, inflammatory markers (hs CRP), NT-proBNP, and renal function.
- Performed standard transthoracic echocardiography (2D and Doppler) to evaluate cardiac structure and function, including left and right ventricular parameters.
Main Results:
- Obese HFpEF patients showed significantly higher diastolic blood pressure, glucose, lipid profiles, uric acid, and hs CRP compared to non-obese HFpEF patients.
- Despite more severe HF symptoms, obese HFpEF patients had lower NT-proBNP levels.
- Echocardiography revealed more pronounced obesity-related left ventricular diastolic dysfunction, increased LV dimensions and mass, and greater right ventricular dilatation and dysfunction in obese HFpEF patients.
Conclusions:
- Obese patients with HFpEF present with elevated cardiovascular risk factors including higher diastolic BP, atherogenic dyslipidemia, and insulin resistance.
- These patients exhibit increased systemic inflammation and echocardiographic evidence of significant left and right ventricular diastolic dysfunction.
- Central obesity in HFpEF portends a higher risk for future cardiovascular events, necessitating targeted interventions.
Related Concept Videos
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:26Imbalances in Cardiac Output
1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:26Heart Failure Drugs: Inotropic Agents
574
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
574